[Ip-health] MSF briefing doc: Barriers to Access and Scale up for hep C treatment - daclatasvir

Joanna Keenan joanna.l.keenan at gmail.com
Tue Apr 21 07:24:31 PDT 2015

Médecins Sans Frontières began introducing hepatitis C virus (HCV)
treatment to several patients in India in 2013. MSF is in the process of
scaling up treatment for HCV in at least eight additional countries, using
direct-acting antiviral (DAA) medicines that have recently come to market
with the potential to revolutionise treatment for people living with HCV.

Given the significant potential to improve HCV treatment using the drug
daclatasvir, developed by Bristol-Myers Squibb, MSF has put together
concerns, comments and recommendations to make daclatasvir available and
affordable in developing countries in the linked briefing document,
Barriers to Access and Scale-Up of Hepatitis C Treatment: Spotlight on

Find it online here:


Joanna Keenan
Press Officer
Médecins Sans Frontières - Access Campaign
P: +41 22 849 87 45
M: +41 79 203 13 02
E: joanna.keenan[at]geneva.msf.org
T: @joanna_keenan


More information about the Ip-health mailing list